Interplay between intergrin-linked kinase and ribonuclease inhibitor affects growth and metastasis of bladder cancer through signaling ILK pathways

Xiang Zhuang, Mengxin Lv, Zhenyu Zhong, Luyu Zhang, Rong Jiang, Junxia ChenJournal of Experimental & Clinical Cancer Research 2016 · DOI

TL;DR

This study reveals a novel interaction between Integrin-linked kinase (ILK) and Ribonuclease inhibitor (RI) in bladder cancer. They found that RI can suppress ILK's pro-cancerous activities, including promoting cell growth, migration, and epithelial-mesenchymal transition (EMT), suggesting a potential therapeutic avenue for bladder cancer.

What Problem Does This Paper Address?

Bladder cancer is a significant health concern, and understanding the molecular mechanisms driving its growth and metastasis is crucial for developing effective treatments. Integrin-linked kinase (ILK) is known to play a role in various cancers, including bladder cancer, by promoting cell movement, cell cycle progression, metastasis, and epithelial-mesenchymal transition (EMT). Ribonuclease inhibitor (RI), a protein with diverse functions, has also been implicated in cellular processes. While previous work hinted at a connection between ILK and RI, the precise nature of their interplay and how it influences bladder cancer progression remained unclear. This paper aims to elucidate this relationship, specifically investigating if RI can directly regulate ILK signaling pathways.

Methods

The researchers employed a multi-pronged approach to investigate the interaction between ILK and RI:

  • Interaction Confirmation:
    • GST pull-down assays: Used to determine if purified RI could directly bind to ILK.
  • Co-immunoprecipitation (Co-IP): Used to confirm the interaction between ILK and RI within cells, both exogenously (introduced) and endogenously (naturally occurring).
  • Fluorescence Resonance Energy Transfer (FRET): A live-cell imaging technique to visualize and confirm the direct physical interaction between ILK and RI in real-time.
  • Confocal microscopy and Immunofluorescence: Used to assess the subcellular localization of ILK and RI and determine if they co-localize within cells.
  • Functional Impact Assessment:
    • Western Blotting: To quantify the protein levels of ILK, RI, and key signaling molecules involved in the PI3K/AKT/mTOR pathway and EMT markers.
  • Immunohistochemistry and Immunofluorescence: To examine protein expression in tumor tissues from mouse xenografts and human samples.
  • Cell morphology and cell cycle analysis (Flow Cytometry): To observe changes in cell shape and distribution across different cell cycle phases.
  • Cell proliferation assays (CCK-8): To measure the rate of cell growth.
  • Mouse xenograft models: To evaluate the in vivo effects of ILK and RI on tumor growth, metastasis, and angiogenesis.

Datasets

The study utilized the following cell lines:

  • EJ cells (bladder cancer cell line)
  • HEK 293 cells (human embryonic kidney cell line, commonly used for protein expression and interaction studies)

Animal models:

  • BALB/C nude mice were used for xenograft tumor studies.

Human samples:

  • Bladder carcinoma and corresponding non-tumor normal tissues were obtained from patients.

Key Insights and Ideas

  • Direct Physical Interaction: The study provides the first direct evidence that ILK and RI physically interact with each other, both in vitro and within cells. This is a significant finding, moving beyond correlational observations.
  • Inverse Correlation: ILK and RI protein levels were found to be inversely correlated in both in vitro cell models and in vivo tumor tissues. This suggests a regulatory relationship where increased ILK is associated with decreased RI, and vice versa.
  • RI as an ILK Suppressor: The research strongly indicates that RI acts as a suppressor of ILK's pro-cancerous functions. Overexpression of RI inhibited cell proliferation, induced cell cycle arrest, and reduced the expression of key pro-metastatic and EMT-related proteins.
  • ILK as a Promoter of Cancer Progression: Conversely, ILK overexpression promoted cell proliferation, induced mesenchymal morphology, and upregulated proteins associated with EMT and metastasis.
  • Mechanism of Action: The interplay between ILK and RI appears to regulate the ILK/PI3K/AKT signaling pathway, which is a critical pathway in cell growth, survival, and metastasis. RI's suppression of ILK also impacts EMT regulators like E-cadherin, Vimentin, Snail, and Twist.
  • Therapeutic Potential: The findings highlight ILK and RI as potential biomarkers for bladder cancer diagnosis and prognosis, and importantly, suggest that RI could be developed as a therapeutic agent to inhibit bladder cancer progression.

Key Results

  • Interaction Confirmation: GST pull-down, Co-IP, and FRET assays all confirmed a direct physical interaction between ILK and RI.
  • Expression Correlation: A significant inverse correlation between ILK and RI protein levels was observed in cell lines and xenograft tumors.
  • RI's Inhibitory Effects: EJ-RI cells (overexpressing RI) showed significantly reduced proliferation, increased G1/S phase arrest, and decreased expression of EMT markers (MMP2, MMP9, N-cadherin, Vimentin, Twist, Snail) compared to control cells.
  • ILK's Promoting Effects: EJ-ILK cells (overexpressing ILK) exhibited increased proliferation, mesenchymal morphology, and elevated expression of EMT markers.
  • In Vivo Efficacy: In xenograft models, EJ-RI tumors showed significantly lower growth and metastasis rates, while EJ-ILK tumors grew larger and metastasized more aggressively.
  • Signaling Pathway Modulation: RI suppressed the phosphorylation of key signaling molecules like p-Akt, p-GSK3β, p-PI3K, and p-mTOR, while ILK promoted their phosphorylation. RI also increased PTEN expression, a known tumor suppressor.
  • Angiogenesis Inhibition: RI suppressed angiogenesis (formation of new blood vessels), while ILK promoted it.

Limitations and Future Work

  • Underlying Molecular Mechanism: While the study demonstrates a physical interaction and functional consequences, the precise molecular details of how RI directly binds to and suppresses ILK activity require further investigation.
  • Broader Clinical Relevance: While human bladder cancer tissues were analyzed, further studies with larger cohorts would strengthen the clinical relevance of ILK and RI as diagnostic and prognostic markers.
  • Therapeutic Development: The paper suggests RI as a potential therapeutic agent. Future work would involve developing and testing RI-based therapies for bladder cancer.
  • Other Cancer Types: The study focused on bladder cancer. Investigating the ILK-RI interplay in other cancer types could reveal broader therapeutic applications.

Summary updated

Abstract

Our findings, for the first time, directly proved that the interplay between ILK and RI regulated EMT via ILK/PI3K/AKT signaling pathways for bladder cancer, which highlights the possibilities that ILK/RI could be valuable markers together for the therapy and diagnosis of human carcinoma of urinary bladder.
BibTeX
@article{zhuang2016interplay,
  author = {Xiang Zhuang and Mengxin Lv and Zhenyu Zhong and Luyu Zhang and Rong Jiang and Junxia Chen},
  title = {{Interplay between intergrin-linked kinase and ribonuclease inhibitor affects growth and metastasis of bladder cancer through signaling ILK pathways}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2016},
  doi = {10.1186/s13046-016-0408-x},
}
Figure